A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 7850 participants.
Also called NCT01794143
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 7,850 participants
- Sponsor
- Registry
-
NCT01794143
-
- Main results
- Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial
- Other papers using this trial's data
- Association of Baseline Factors With Glycemic Outcomes in GRADE: A Comparative Effectiveness Randomized Clinical Trial
- Association of Hospitalizations With Randomized Glycemia-Lowering Treatment in GRADE
- Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study)
- Comparative Effects of Randomized Second-line Therapy for Type 2 Diabetes on a Composite Outcome Incorporating Glycemic Control, Body Weight, and Hypoglycemia: An Analysis of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
- Differences in Prevalence and Incidence of Electrocardiogram Abnormalities and Cardiovascular Autonomic Neuropathy Among Randomized Glucose-Lowering Treatments in Early Type 2 Diabetes: The Glycemia Reduction Approaches in Diabetes (GRADE) Cohort
- Differential Treatment Effects on β-Cell Function Using Model-Based Parameters in Type 2 Diabetes: Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
- Differential associations of somatic and cognitive-affective symptoms of depression with inflammation and insulin resistance: cross-sectional and longitudinal results from the Emotional Distress Sub-Study of the GRADE study
- Does Emotional Distress Predict Worse Glycemic Control Over Time? Results From the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
- Emotional Distress Predicts Reduced Type 2 Diabetes Treatment Adherence in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
- Glucose-Lowering Medications, Glycemia, and Cognitive Outcomes: The GRADE Randomized Clinical Trial
- Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes
- Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes
- Glycemia reduction in type 2 diabetes-Hypoglycemia outcomes: A randomized clinical trial
- Impact of Glucose-Lowering Medications on Health-Related Quality of Life in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
- Impact of Insulin Sensitivity and β-Cell Function Over Time on Glycemic Outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE): Differential Treatment Effects of Dual Therapy
- Lack of Association of Emotional Distress With Insulin Initiation in the GRADE Randomized Diabetes Comparative Effectiveness Trial
- Longitudinal Effects of Glucose-Lowering Medications on β-Cell Responses and Insulin Sensitivity in Type 2 Diabetes: The GRADE Randomized Clinical Trial
- Optimization of Metformin in the GRADE Cohort: Effect on Glycemia and Body Weight
- Relationship Between Average Glucose Levels and HbA1c Differs Across Racial Groups: A Substudy of the GRADE Randomized Trial
- The Use of Rescue Insulin in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE)
- The cross-sectional association of cognition with diabetic peripheral and autonomic neuropathy-The GRADE study
- Use of comprehensive recruitment strategies in the glycemia reduction approaches in diabetes: A comparative effectiveness study (GRADE) multi-center clinical trial
- Weight Gain Was Associated With Worsening Glycemia and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes Independent of Diabetes Medication in the GRADE Randomized Controlled Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01794143. Randomized; no masking; primary purpose treatment. Start 2013-05 (registry gives no type); primary completion 2021-04-30 (actual). Results posted on 2026-02-10.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes
- Acronym
- GRADE
- Condition
- Type 2 Diabetes
- Condition
- Comparative Effectiveness of Glycemia-lowering Medications
- Intervention (Drug)
- Sulfonylurea (glimepiride)
- Intervention (Drug)
- DPP-4 inhibitor (sitagliptin)
- Intervention (Drug)
- GLP-1 receptor agonist (liraglutide)
- Intervention (Drug)
- Insulin (glargine)
- Lead sponsor
- GRADE Study Group
- Collaborator
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator
- Centers for Disease Control and Prevention
Record details
- Record id
cardio:ct-nct01794143- Content hash
cbee5d58bdd611dd2fb1f5b30a818a54fec9f04dea56845bea71f2441bc26a37